Balchem Corporation reported a notable increase in financial performance for the second quarter of 2026, with net sales reaching $283.997 million, an 11.2% rise from $255.467 million in the same period of 2025. The company's gross margin also improved, totaling $103.683 million, up 11.4% from $93.113 million year-over-year. Net earnings for the quarter were $44.615 million, reflecting a 16.6% increase compared to $38.278 million in the prior year. This growth was attributed to higher sales across all segments, particularly in Human Nutrition & Health and Animal Nutrition & Health, which saw increases of 10.0% and 15.0%, respectively.

In the first half of 2026, Balchem's net sales totaled $554.706 million, a 9.6% increase from $505.986 million in the first half of 2025. The gross margin for this period was $204.767 million, up 13.0% from $181.281 million. Operating expenses also rose, totaling $89.920 million, a 14.1% increase from $78.824 million, primarily due to higher compensation-related costs. Despite the increase in expenses, earnings from operations improved to $114.847 million, a 12.1% increase from $102.457 million in the previous year.

The company experienced significant operational changes, including a stock repurchase program initiated in December 2025, which allows for the repurchase of up to 4 million shares. As of June 30, 2026, Balchem had repurchased 342,788 shares under this program. The company also reported a decrease in cash and cash equivalents to $63.174 million from $74.570 million at the end of 2025, while working capital increased to $242.669 million, up from $189.230 million.

Balchem's employee headcount stood at approximately 1,379 as of June 30, 2026, reflecting stable labor market conditions that support the company's recruitment and retention efforts. The company continues to invest in technology solutions to enhance productivity and operational efficiencies. Looking ahead, Balchem remains focused on pursuing acquisitions and expanding its market presence, while also navigating challenges such as geopolitical tensions and evolving trade policies that may impact its operations and financial performance.

About BALCHEM CORP

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products across Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products segments. Its offerings include human-grade choline nutrients, mineral amino acid chelates, MSM, vitamin K2, microencapsulated animal nutrition products, and performance gases like ethylene oxide for medical sterilization. Serving global food, pharmaceutical, animal health, and industrial markets, Balchem leverages proprietary technologies and scientific expertise to deliver high-quality, value-added solutions.

This description was generated via AI from an annual report. Updated about 1 year ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.

View the complete official filing on the SEC website.

Read on SEC.gov